The aftermath of orbital radiotherapy for Graves' ophthalmopathy

Ophthalmology

Volumn 109, Issue 11, 2002, Pages 2100-2107

  Gorman, Colum A ^a   Garrity, James A ^a   Fatourechi, Vahab ^a   Bahn, Rebecca S ^a   Petersen, Ivy A ^a   Stafford, Scott L ^a   Earle, John D ^a   Forbes, Glenn S ^a   Kline, Robert W ^a   Buettner, Helmut ^a   Robertson, Dennis M ^a   Bergstralh, Erik J ^a   Offord, Kenneth P ^a   Rademacher, Diana M ^a   Stanley, Nancy M ^a   Bartley, George B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THYROID STIMULATING IMMUNOGLOBULIN;

ARTICLE; CLINICAL ARTICLE; DECOMPRESSION SURGERY; DIPLOPIA; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; EYE SURGERY; FLUORESCENCE ANGIOGRAPHY; GRAVES DISEASE; HUMAN; OPHTHALMOPLEGIA; ORBIT; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT OUTCOME;

ADULT; AGED; DECOMPRESSION, SURGICAL; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; MALE; MIDDLE AGED; ORBIT; THYROXINE; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 0036841646     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(02)01293-9     Document Type: Article

References (26)

1. Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001;108:1523-34.
2. Morris JC III, Hay ID, Nelson RE, Jiang NS. Clinical utility of thyrotropin-receptor antibody assays: Comparison of radioreceptor and bioassay methods. Mayo Clin Proc 1988;63:707-17.
3. Guides to the Evaluation of Permanent Impairment. The Visual System. Chicago: American Medical Association, 2000; chap. 12, 277-300.
4. Gerling J, Lieb B, Kommerell G. Duction ranges in normal probands and patients with Graves' ophthalmopathy, determined using the Goldmann perimeter. Int Ophthalmol 1998;21:213-21.
5. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992;326:581-8.
6. Younge BR. Eye examination techniques in Graves' ophthalmopathy. In: Gorman CA, Waller RR, Dyer JA, eds. The Eye and Orbit in Thyroid Disease. New York: Raven, 1984;143-53.
7. Farnsworth D. The Farnsworth Dichotomous Test for Color Blindness, Panel D-15. New York: The Psychological Corporation, 1947;1-8.
8. McKenzie JM, Zakarija M, Sato A. Humoral immunity in Graves' disease. Clin Endocrinol Metab 1978;7:31-45.
9. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol 1995;42:45-50.
10. Order SE, Donaldson SS. Radiation Therapy of Benign Diseases: A Clinical Guide, 2nd Rev Ed. New York: Springer-Verlag, 1998:119-27.
11. Mourits MP, van Kempen-Harteveld ML, García MBG, et al. Radiotherapy for Graves' orbitopathy. Randomised placebo-controlled study. Lancet 2000;355:1505-9.
12. Maalouf T, George JL, Angioi-Duprez K, et al. Effects of orbital radiotherapy on extraocular muscles in Graves' ophthalmopathy. Orbit 1996;15:25-32.
13. Van Ruyven RLJ, Van Den Bosch WA, Mulder PGH, et al. The effect of retrobulbar irradiation on exophthalmos, ductions and soft tissue signs in Graves' ophthalmopathy: A retrospective analysis of 90 cases. Eye 2000;14:761-4.
14. Seegenschmiedt MH, Katalinic A, Makoski HB, et al. Radiation therapy for benign diseases: Patterns of care study in Germany. Int J Radiat Oncol Biol Phys 2000;47:195-202.
15. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-1602.
16. Margo CE. The placebo effect. Surv Ophthalmol 1999;44:31-44.
17. Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol 1997;123:455-64.
18. Snijders-Keilholz A, De Keizer RJW, Goslings BM, et al. Probable risk of tumour induction after retro-orbital irradiation for Graves' ophthalmopathy. Radiother Oncol 1996;38:69-71.
19. Nygaard B, Specht L. Transitory blindness after retrobulbar irradiation of Graves' ophthalmopathy [letter]. Lancet 1998;351:725-6.
20. Appelqvist P, Salmo M, Rissanen P. Radiotherapy in emergency treatment of malignant exophthalmos. Strahlenther Onkol 1990;166:190-3.
21. Kinyoun JL, Kalina RE, Browner SA, et al. Radiation retinopathy after orbital irradiation for Graves' ophthalmopathy. Arch Ophthalmol 1984;102:1473-6.
22. Miller ML, Goldberg SH, Bullock JD. Radiation retinopathy after standard radiotherapy for thyroid-related ophthalmopathy [letter]. Am J Ophthalmol 1991;112:600-1.
23. Bahn RS, Dutton CM, Natt N, et al. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: Potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 1998;83:998-1002.
24. DeGroot LJ, Benjasuratwong Y. Evaluation of thyroid ablative therapy for ophthalmopathy of Graves' disease. Orbit 1996;15:187-96.
25. Gerding MN, van der Meer JWC, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol 2000;52:267-71.
26. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996;125:605-13.